英格兰与AstraZeneca COVID-19疫苗相关的基层医疗费用
该研究利用ORCHID基层医疗电子记录和NHS收费标准,对2020至2021年英格兰接种AstraZeneca COVID-19疫苗(AZD1222)者与未接种者进行经济分析。结果显示,接种首剂者接种后15天总费用低47.5英镑(95%CI:42.6至52.4),30天低87.1英镑(95%CI:79.6至94.6),45天低124.0英镑(95%CI:114.3至133.7)。
要点
- 接种首剂AstraZeneca疫苗者15天总费用低47.5英镑(95%CI:42.6至52.4)。
- 30天费用低87.1英镑(95%CI:79.6至94.6),45天低124.0英镑(95%CI:114.3至133.7)。
- 该期间费用降幅约为33.1%。
核心结论
- 接种AstraZeneca COVID-19疫苗首剂者较未接种者基层医疗总费用显著更低。
研究设计与样本
- 利用ORCHID基层医疗电子记录、按NHS收费标准计价的经济分析,采用时变精确粗化匹配平衡接种与未接种组特征。
主要发现
- 接种后15天,接种组总费用较未接种组低47.5英镑(95%CI:42.6至52.4)。
- 接种后30天,接种组总费用较未接种组低87.1英镑(95%CI:79.6至94.6)。
- 接种后45天,接种组总费用较未接种组低124.0英镑(95%CI:114.3至133.7),该期间降幅约33.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current research on the effectiveness of COVID-19 vaccines has demonstrated their role in reducing hospitalizations and deaths due to SARS-CoV-2. However, evidence regarding the healthcare costs incurred by vaccinated versus unvaccinated individuals in the community remains limited, especially in primary care, the first point of access for most patients. This study estimated the total (all-cause) primary healthcare costs for individuals who received the AstraZeneca COVID-19 vaccine (AZD1222) in England between 2020 and 2021. We conducted an economic analysis utilizing electronic primary healthcare records from the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) database, with costs valued according to NHS tariffs. Exact coarsened matching in a time-varying setting was employed to balance patient characteristics between the vaccinated and unvaccinated groups. Our results indicate that vaccinated individuals who received the first dose of the AstraZeneca vaccine incurred significantly lower primary healthcare costs compared to their unvaccinated counterparts. Specifically, at 15 days post-vaccination, vaccinated individuals had total costs that were £47.5 (95 % CI: £42.6 to £52.4) lower. This difference increased to £87.1 (95 % CI: £79.6 to £94.6) at 30 days and £124.0 (95 % CI: £114.3 to £133.7) at 45 days post-vaccination, reflecting a reduction of approximately 33.1 % during this period. These findings carry important implications for healthcare budgeting, resource allocation, and pandemic response policies.
引用
- Madia JE, Nicodemo C, Petrou S, et al. Primary healthcare costs associated with the AstraZeneca COVID-19 vaccine in England. Vaccine. 2025. PMID: 41412017. doi:10.1016/j.vaccine.2025.128067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。